ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Atherogenic Combined Index is Independently Associated with MASLD in Type 2 Diabetes: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unveiling sex-specific cardiometabolic and adiposity risk profiles for precision prevention.European journal of medical research · 2026Article
- The Relationship Between Visceral Fat Obesity and the Atherogenic Combined Index in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Metabolic dysfunction-associated steatotic liver disease (MASLD) is commonly associated with metabolic disorders such as obesity, diabetes and dyslipidemia. Previous studies have explored the relationship between traditional lipid parameters and MASLD. The atherogenic combined index (ACI), a novel non-traditional lipid marker, has recently been proposed as a potential indicator of coronary artery disease. The relationship between the ACI and MASLD remains unclear. This study aims to investigate this relationship in patients with type 2 diabetes (T2D). Methods: This cross-sectional study analyzed 2703 patients with T2D. Ultrasound was used to assess MASLD. The clinical and biochemical data were gathered. The ACI was calculated as the base-10 logarithm of the product of triglyceride and non-high-density lipoprotein cholesterol divided by high-density lipoprotein cholesterol. Statistical analyses explored the association between the ACI and MASLD. Results: Compared to the non-MASLD group, the ACI was higher in the MASLD group (P < 0.001). Spearman correlation analysis revealed a positive association between ACI and MASLD (P < 0.001). Logistic regression analysis showed that the ACI was independently associated with MASLD. Compared with participants in the lowest ACI quartile (Q1), Q4 (OR: 3.636, 95% CI: 2.361-5.601) showed significantly increased risks of MASLD (P < 0.001). Subgroup analyses confirmed that the significant association between ACI and MASLD was consistent across sex (females and males), body mass index (BMI < 24 kg/m² and BMI ≥ 24 kg/m²) and age groups (age < 60 years and age ≥ 60 years). Conclusion: The ACI is independently correlated with MASLD in T2D patients, supporting its potential as a useful marker for MASLD screening and management in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.